2023年 · 第103卷第14期

Polycystic ovary syndrome (PCOS) is the most common reproductive endocrine metabolic disease in women of childbearing age. Most patients are overweight or obese, especially increased visceral fat (VAT) interacts with hyperandrogenic status and insulin resistance (IR) to form a vicious circle. Weight-loss diet is the first-line treatment for PCOS, but there is limited evidence of the effect of energy-limited meals (CRD) on VAT, while recent studies have shown that glucagon-like peptide 1 receptor agonist (GLP-1 RA) can significantly reduce body weight and VAT in patients with PCOS. Therefore, the aim of this study was to evaluate the improvement of fat distribution, androgenic status, and metabolic indicators in overweight/obese PCOS patients with GLP-1 RA weekly formulation dulaglutide with or without CRD with equivalent weight loss.

Polycystic ovary syndrome (PCOS) is the most common endocrine disease in women of childbearing age. Insulin resistance (IR) plays a key role in the pathogenesis of PCOS, which exists in most patients with PCOS, especially in overweight and obese people. Metformin is able to reduce IR and is therefore recommended for patients with PCOS to improve ovulation and metabolic abnormalities and reduce androgen levels. However, the variability and unmeasurability of the response to metformin treatment in patients with PCOS limits its wide application. Artificial neural network (ANN) is a mathematical method especially suitable for analyzing the nonlinear correlation between independent variables such as PCOS. Therefore, this study aimed to apply ANN to determine reliable predictors of response to metformin treatment in patients with PCOS.

Polycystic ovary syndrome (PCOS) is the most common endocrine disease in women of childbearing age, and obesity is closely associated with PCOS, so weight loss is essential for managing obese PCOS. Lifestyle interventions are the first-line treatment for obese PCOS, but the weight loss effect is limited, thus requiring drug therapy as an adjunct. The glucagon-like peptide 1 receptor agonist (GLP-1RA) liraglutide (LIRA) 3 mg once daily has been approved for weight loss treatment in obese patients, which can reduce body weight by about 5% to 10%. Therefore, the aim of this study was to investigate the efficacy and safety of LIRA 3 mg in reducing body weight and hyperandrogenism in obese women with PCOS.